A Phase 3 interventional study of Symbicort Turbuhaler and Terbutaline Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 2 sites in Japan. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 215th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2009, is one of 121 in phase 3, and was the 121st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 16 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler
Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler
160/4.5μg for 3 days
0.4 mg for 3 days
Adverse Events
Total number of adverse events
Time frame: 3 days
Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
Time frame: up to 740 min after start dosing for each treatment day
Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
Time frame: up to 140 min after start dosing for each treatment day
Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)
The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
Time frame: up to 740 min after start dosing for each treatment day
Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
Time frame: up to 740 min after start dosing for each treatment day
Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
Time frame: up to 740 min after start dosing for each treatment day
Patients recruited from 2 hospitals in Japan between January 2009 and July 2009. 28 patients enrolled; 25 patients randomized, 3 patients were not randomized (1 due to incorrect enrollment and 2 due to adverse event)
| Milestone | Symbicort First, Then Terbutaline | Terbutaline First, Then Symbicort |
|---|---|---|
| Started | 13 | 12 |
| Completed | 13 | 12 |
| Not completed | 0 | 0 |
| Milestone | Symbicort First, Then Terbutaline | Terbutaline First, Then Symbicort |
|---|---|---|
| Started | 13 | 12 |
| Completed | 11 | 12 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Milestone | Symbicort First, Then Terbutaline | Terbutaline First, Then Symbicort |
|---|---|---|
| Started | 11 | 12 |
| Completed | 11 | 12 |
| Not completed | 0 | 0 |
Total number of adverse events
| adverse events | Symbicort | Terbutaline |
|---|---|---|
| Adverse Events | 14 | 24 |
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
| mEq/L | Symbicort | Terbutaline |
|---|---|---|
| Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC) | 4.01 ± 0.25 | 3.88 ± 0.26 |
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
| mg/dLiters | Symbicort | Terbutaline |
|---|---|---|
| Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC) | 121.1 ± 20.3 | 129.5 ± 22.0 |
The mean AUC of QTcF (ECG interval measured from the beginning of the Q wave to the end of the T wave, corrected for heart rate using Fridericia's formula)was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
| ms | Symbicort | Terbutaline |
|---|---|---|
| Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC) | 411.71 ± 15.07 | 414.33 ± 14.04 |
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
| mmHg | Symbicort | Terbutaline |
|---|---|---|
| Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC) | 115.3 ± 6.3 | 114.9 ± 8.0 |
The mean AUC value was calculated as AUC (calculated using the trapezoidal method) divided by the length of the sampling period.
| beats/min | Symbicort | Terbutaline |
|---|---|---|
| Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC) | 70.0 ± 6.6 | 74.1 ± 7.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort | — | 0/25 (0%) | 7/25 (28%) |
| Terbutaline | — | 0/23 (0%) | 15/23 (65.2%) |
| Event | Symbicort | Terbutaline |
|---|---|---|
| TremorNervous system disorders | 3/25 | 4/23 |
| PalpitationsCardiac disorders | 1/25 | 3/23 |
| TachycardiaCardiac disorders | 1/25 | 3/23 |
| Blood Pressure DecreasedInvestigations | 2/25 | 3/23 |
| NasopharyngitisInfections and infestations | 2/25 | 2/23 |
| Age Continuous(years) | All Study Participants |
|---|---|
| Mean | 44.3 ± 14.8 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 15 |
| Male | 10 |
The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol